XRCC1基因多态性对晚期胃癌患者化疗疗效及生存期的影响  

Effects of XRCC1 Polymorphism on Efficacy of Chemotherapy and Survival Time of Advanced Gastric Cancer Patients

作　　者：钟兰[1] 符生苗[2] 谢贤和[3] 黄涛[1] 高允锁[4] 林瑜[1] 

机构地区：[1]海南省人民医院检验科,海口570311 [2]海南省人民医院医学检验中心,海口570311 [3]福建医科大学附属第一医院化疗科,福州350005 [4]海南省人民医院医学装备处,海口570311

出　　处：《中国药房》2017年第14期1873-1876,共4页China Pharmacy

基　　金：海南省医学普通科研课题(No.琼卫2012PT-17)

摘　　要：目的:考察X射线损伤修复交叉互补基因1(XRCC1)Arg399Gln(G→A)多态性对晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及生存期的影响。方法:选取2013年1月-2015年1月海南省人民医院晚期胃癌患者52例,予奥沙利铂+氟尿嘧啶联合化疗,每3周为1个周期,均治疗3个周期以上。采用聚合酶链反应-连接酶检测反应法测定患者的基因型,比较不同基因型患者的疾病控制率和无进展生存期。结果:52例晚期胃癌患者中,XRCC1 GG基因型28例(53.8%)、GA基因型21例(40.4%)、AA基因型3例(5.8%),各基因型频率均符合Hardy-Weinberg平衡(P>0.05)。52例患者的疾病控制率为76.9%,其中GG基因型患者的疾病控制率(92.9%)显著高于GA+AA基因型(58.3%),差异有统计学意义(P<0.05);52例患者的平均无进展生存期为(7.1±1.2)个月,其中GG基因型患者的无进展生存期[(8.6±0.8)个月]显著长于GG+GA基因型[(5.9±0.7)个月],差异有统计学意义(P<0.05)。结论:XRCC1多态性与晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及无进展生存期有关,且XRCC1 GG基因型患者对化疗药物更敏感;该基因可能成为该类方案化疗疗效及生存期的预测标志物。OBJECTIVE： To investigate the effect of X-ray repair cross complementing gene （XRCC1） Arg399Gln （C→A） polymorphism on efficacy of oxaliplatin＋fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METHODS： Totally 52 cases of advanced gastric cancer were selected from Hainan Provincial People＇s Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin＋fluorouracil chemotherapy, for 3 courses （a treatment course lasted for 3 weeks）. The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different geno- types. RESULTS： Among 52 cases of advanced gastric cancer, there were 28 cases of XRCC1 GG genotype （53.8%）, 21 cases of GA genotype （40.4%）, 3 cases of AA genotype （5.8%）, frequencies of which were all in line with Hardy-Weinberg balance （P〉 0.05）. Disease control rates of 52 cases were 76.9%, among which disease control rate （92.9%） of GG genotype was significantly higher than that of GA＋AA genotype （58.3%）, with statistical significance （P〈0.05）. The average progression free survival of 52 cases was （7.1±1.2） months, among which progression free survival of GG genotype [ （8.6 ± 0.8） months] was significantly longer than that of GG＋GA genotype [（5.9 ± 0.7）months], with statistical significance （P〈0.05）. CONCLUSIONS： XRCC1 polymor- phism is correlated with efficacy of oxaliplatin＋fluorouracil chemotherapy and progression free survival, and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemothera- py and survival.

关 键 词：XRCC1 基因多态性 晚期胃癌 奥沙利铂 氟尿嘧啶 化疗疗效 无进展生存期 

分 类 号：R735[医药卫生—肿瘤]